XBI ETF holdings (NYSE) - Page 8 | MetaTrader

Abrir gráfico completo Full chart

Visão geral Todos os ativos Mapa de calor

Principais ativos Market Value Shares Weight %

SVRA Savara Inc 8.978 M 1.489 M 0.114%

ERAS Erasca Inc 8.076 M 2.171 M 0.103%

MDXG MiMedx Group Inc 7.774 M 1.148 M 0.099%

CONTRA METSERA INC 7.500 M 1.531 M 0.096%

TYRA Tyra Biosciences Inc 6.733 M 256.100 K 0.086%

RZLT Rezolute Inc 5.451 M 2.310 M 0.069%

State Street Global Advisors 4.591 M 4.591 M 0.058%

IRWD Ironwood Pharmaceuticals Inc 3.621 M 1.074 M 0.046%

CONTRA AKERO THERAPEUT 1.322 M 2.034 M 0.017%

CONTRA INHIBRX INC 1.070 M 1.646 M 0.014%

CONTRA MIRATI THERAPEU 958.686 K 1.370 M 0.012%

CONTRA VERVE THERAPEUT 567.172 K 900.273 K 0.007%

CONTRA BLUEPRINT MEDIC 347.976 K 756.469 K 0.004%

OMNIAB INC 161.959 K

1
2
3
4
5
6
7
8

Notícias

First Quarter Earnings: Sharpening Sector Divergence

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

3 Reasons To Stick With Growth Stocks In Rotating Markets

Seeking Innovation Beyond Tech? Insight On Healthcare Stocks

Biotech Investors Are Tuning Out the MAHA Chaos

Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Preço-alvo da Capricor mantido em US$ 63 pela B.Riley com avanços na FDA

FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint

Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)

Juros a descoberto da Intellia lideram alta entre biotechs, diz Baird

Mizuho reduz preço-alvo da Immunocore para US$ 34 após revisão de receita